Literature DB >> 20837666

Angiotensin-(1-7) reduces fibrosis in orthotopic breast tumors.

Katherine L Cook1, Linda J Metheny-Barlow, E Ann Tallant, Patricia E Gallagher.   

Abstract

Angiotensin-(1-7) [Ang-(1-7)] is an endogenous 7-amino acid peptide hormone of the renin-angiotensin system that has antiproliferative properties. In this study, Ang-(1-7) inhibited the growth of cancer-associated fibroblasts (CAF) and reduced fibrosis in the tumor microenvironment. A marked decrease in tumor volume and weight was observed in orthotopic human breast tumors positive for the estrogen receptor (BT-474 or ZR-75-1) and HER2 (BT-474) following Ang-(1-7) administration to athymic mice. Ang-(1-7) concomitantly reduced interstitial fibrosis in association with a significant decrease in collagen I deposition, along with a similar reduction in perivascular fibrosis. In CAFs isolated from orthotopic breast tumors, the heptapeptide markedly attenuated in vitro growth as well as reduced fibronectin, transforming growth factor-β (TGF-β), and extracellular signal-regulated kinase 1/2 kinase activity. An associated increase in the mitogen-activated protein kinase (MAPK) phosphatase DUSP1 following treatment with Ang-(1-7) suggested a potential mechanism by which the heptapeptide reduced MAPK signaling. Consistent with these in vitro observations, immunohistochemical analysis of Ang-(1-7)-treated orthotopic breast tumors revealed reduced TGF-β and increased DUSP1. Together, our findings indicate that Ang-(1-7) targets the tumor microenvironment to inhibit CAF growth and tumor fibrosis. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20837666      PMCID: PMC9169411          DOI: 10.1158/0008-5472.CAN-10-1136

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  49 in total

1.  Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension.

Authors:  Justin L Grobe; Adam P Mecca; Haoyu Mao; Michael J Katovich
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-01-13       Impact factor: 4.733

2.  Altered profiles of estradiol and progesterone associated with prolonged estrous cycles and persistent vaginal cornification in aging C57BL/6J mice.

Authors:  J F Nelson; L S Felicio; H H Osterburg; C E Finch
Journal:  Biol Reprod       Date:  1981-05       Impact factor: 4.285

3.  Extracellular matrix proteins and their receptors in the normal, hyperplastic and neoplastic breast.

Authors:  V E Gould; G K Koukoulis; I Virtanen
Journal:  Cell Differ Dev       Date:  1990-12-02

4.  Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect.

Authors:  Yuval Sheffer; Oded Leon; Jehonathan H Pinthus; Arnon Nagler; Yoram Mor; Olga Genin; Maya Iluz; Norifumi Kawada; Katsutoshi Yoshizato; Mark Pines
Journal:  Mol Cancer Ther       Date:  2007-01-31       Impact factor: 6.261

Review 5.  High interstitial fluid pressure - an obstacle in cancer therapy.

Authors:  Carl-Henrik Heldin; Kristofer Rubin; Kristian Pietras; Arne Ostman
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

6.  Collagen type I induces disruption of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells.

Authors:  Alexander Koenig; Claudia Mueller; Cornelia Hasel; Guido Adler; Andre Menke
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

7.  Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.

Authors:  Grazia Arpino; Carolina Gutierrez; Heidi Weiss; Mothaffar Rimawi; Suleiman Massarweh; Lavina Bharwani; Sabino De Placido; C Kent Osborne; Rachel Schiff
Journal:  J Natl Cancer Inst       Date:  2007-05-02       Impact factor: 13.506

8.  Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?

Authors:  A F Lever; D J Hole; C R Gillis; I R McCallum; G T McInnes; P L MacKinnon; P A Meredith; L S Murray; J L Reid; J W Robertson
Journal:  Lancet       Date:  1998-07-18       Impact factor: 79.321

9.  Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product.

Authors:  B R Dey; V P Sukhatme; A B Roberts; M B Sporn; F J Rauscher; S J Kim
Journal:  Mol Endocrinol       Date:  1994-05

Review 10.  Targeting the tumor stroma in cancer therapy.

Authors:  Kevin Anton; John Glod
Journal:  Curr Pharm Biotechnol       Date:  2009-02       Impact factor: 2.837

View more
  30 in total

1.  Angiotensin-(1-7) attenuates angiotensin II-induced cardiac remodeling associated with upregulation of dual-specificity phosphatase 1.

Authors:  Latronya T McCollum; Patricia E Gallagher; E Ann Tallant
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-12-02       Impact factor: 4.733

2.  Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis.

Authors:  Bhavani Krishnan; Thomas L Smith; Purnima Dubey; Michael E Zapadka; Frank M Torti; Mark C Willingham; E Ann Tallant; Patricia E Gallagher
Journal:  Prostate       Date:  2012-05-29       Impact factor: 4.104

3.  Identification of intracellular proteins and signaling pathways in human endothelial cells regulated by angiotensin-(1-7).

Authors:  Christian Meinert; Florian Gembardt; Ilka Böhme; Anja Tetzner; Thomas Wieland; Barry Greenberg; Thomas Walther
Journal:  J Proteomics       Date:  2015-09-24       Impact factor: 4.044

4.  Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors.

Authors:  Benjamin Diop-Frimpong; Vikash P Chauhan; Stephen Krane; Yves Boucher; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

5.  Angiotensin-(1-7) prevents radiation-induced inflammation in rat primary astrocytes through regulation of MAP kinase signaling.

Authors:  Elizabeth D Moore; Mitra Kooshki; Linda J Metheny-Barlow; Patricia E Gallagher; Mike E Robbins
Journal:  Free Radic Biol Med       Date:  2013-09-03       Impact factor: 7.376

6.  Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft.

Authors:  Nataly Tarasenko; Abraham Nudelman; Gabriela Rozic; Suzanne M Cutts; Ada Rephaeli
Journal:  Invest New Drugs       Date:  2017-03-17       Impact factor: 3.850

7.  Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models.

Authors:  Chandraiah Godugu; Apurva R Patel; Ravi Doddapaneni; Srujan Marepally; Tanise Jackson; Mandip Singh
Journal:  J Control Release       Date:  2013-07-07       Impact factor: 9.776

Review 8.  The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7).

Authors:  Robson Augusto Souza Santos; Walkyria Oliveira Sampaio; Andreia C Alzamora; Daisy Motta-Santos; Natalia Alenina; Michael Bader; Maria Jose Campagnole-Santos
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

9.  Angiotensin-(1-7) Suppresses Hepatocellular Carcinoma Growth and Angiogenesis via Complex Interactions of Angiotensin II Type 1 Receptor, Angiotensin II Type 2 Receptor and Mas Receptor.

Authors:  Yanping Liu; Bin Li; Ximing Wang; Guishuang Li; Rui Shang; Jianmin Yang; Jiali Wang; Meng Zhang; Yuguo Chen; Yun Zhang; Cheng Zhang; Panpan Hao
Journal:  Mol Med       Date:  2015-07-27       Impact factor: 6.354

10.  The angiotensin-converting enzyme 2/angiotensin (1-7)/Mas axis protects against lung fibroblast migration and lung fibrosis by inhibiting the NOX4-derived ROS-mediated RhoA/Rho kinase pathway.

Authors:  Ying Meng; Ting Li; Gao-Su Zhou; Yan Chen; Chang-Hui Yu; Miao-Xia Pang; Wei Li; Yang Li; Wen-Yong Zhang; Xu Li
Journal:  Antioxid Redox Signal       Date:  2014-10-02       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.